News, musings and commentary on dietary supplements & pharmaceutical law issues, technology, and litigation.
Lawyers for consumers and injured people.(No advice on this blog, though)
Wednesday, September 26, 2012
Tresiba CV risk?
The FDA has told Novo Nordisk that an FDA Advisory Committee meeting is tentatively scheduled to be held on November 8, 2012 to discuss the New Drug Applications for the ultra-long-acting insulin Tresiba (insulin degludec) and insulin combination analogue Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes. There is also a report from JP Morgan detailing the CV risk, found here: https://mm.jpmorgan.com/stp/t/c.do?i=2A970-73A&u=a_p*d_940113.pdf*h_-dgbn7cl%250d%250a